2020 Meeting Dates
- January 16, 2020
- April 16, 2020
- July 16, 2020
- October 16, 2020
Meetings are scheduled to begin at 9:00 am at the Idaho Medicaid Offices at 3232 Elder Street, Boise, ID 83705.
State of Idaho Drug Utilization Review Program
The Idaho Drug Utilization Review (DUR) Program was established in 1993 to fulfill specific requirements of the Omnibus Budget Reconciliation Act of 1990 (OBRA 90) as a contingency for the Idaho Department of Health and Welfare to receive federal funding. The DUR program uses a structured process to review claims data and interpret patterns of drug use in relation to predetermined criteria. The goals of the program are to reduce potentially inappropriate prescribing and dispensing of medications, enhance the counseling of patients, and reduce growth in expenditures for drugs.
The Director of the Idaho Department of Health and Welfare appoints the members of the DUR Board which consists of three practicing Idaho physicians, three practicing Idaho pharmacists and a practicing Idaho Nurse Practitioner or Physician Assistant. Medicaid contracts with Magellan Medicaid Administration to provide support to the Board. The Board meets four times each year. Members are asked to serve three year terms and are paid a modest honorarium for their time. A major component of the DUR program is retrospective population-based review of drug claims data and other records to identify prescribing and dispensing patterns for potential problems such as drug-disease contraindications, drug-drug interactions, incorrect drug dosage, incorrect duration of drug treatment, over and under utilization, and therapeutic duplication. Beneficiary profiles are screened against predetermined criteria developed from peer-reviewed medical literature and standard drug compendia. Board members are blinded to the identity of prescribers and beneficiaries. If a patient profile does not meet the criteria, an educational intervention is undertaken. These interventions take the form of educational leaflets, face to face visits, continuing education programs, and informational newsletters. The DUR Board also conducts outcome studies to ensure that Medicaid cost containment strategies have had a positive effect and have not resulted in negative outcomes for our beneficiaries.
Perry Brown, MD (Physician, Boise)
Dr. Brown serves as Director of Pediatric Education at the Family Medicine Residency of Idaho and as Assistant Director of the Cystic Fibrosis Center of Idaho. Additionally, he is an assistant clinical professor at the University of Washington School of Medicine. He has been in practice in Idaho since 1998 and is a member of the Idaho Medical Association. He has been serving on the Pharmacy and Therapeutics Committee for Idaho Medicaid since January 2009. He was appointed to the Drug Utilization Review Board in 2008.
Paul Cady, MS, PhD (Pharmacist, Pocatello)
Paul Cady is Dean at Idaho State University College of Pharmacy. He earned his B.S. in pharmacy in 1980 from the University of Arizona. After serving with the Indian Health Service in 1984 he returned to the University of Arizona and earned his M.S and Ph.D in pharmacy administration. Dr Cady was on faculty at the University of Tennessee College of Pharmacy for two years prior to his appointment to the Idaho State University College of Pharmacy faculty. While at Idaho State University, Dr. Cady has served as the Director of the Pharmacy Administration Graduate Program and as Vice Chair in the Department of Pharmacy Practice and Administrative Sciences. He was a recipient of the Lyman Award in 1998. His research interests include population based drug utilization review and pharmacoeconomics.
Meeting Agendas can be found at the Magellan Medicaid Administration website: https://idaho.fhsc.com/providers/dur.asp
Meeting Minutes can be found at the Magellan Medicaid Administration
Mark England, PharmD
Magellan Medicaid Administration